btlines

BGD NewConnect Periodic report · PAP Biznes

Biogened SA (BGD) · Q2 2026 results

Share price: 18.50 zł · 2026-11-10

Results Q2 2026 vs Q2 2025 · year over year · published 14 Aug 2026 and 14 Aug 2025

Net income down 4.3% year on year. The report's language is unchanged.

Only a basic analysis is available for this company at the moment.

1 · Numbers

−4.3%

Net income vs Q2 2025

Net income 1.4M vs 1.4M

2 · How the report reads

Unchanged

Language tone vs last period

Report language: very upbeat for a company report — about as upbeat as in Q2 2025.

Weak signal: formal report language, not a call.

3 · What stood out Nothing unusual flagged this period.

Read between the lines

No major shifts flagged this period.

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q2 2025.

Report language Very upbeat (was very upbeat)

Very upbeat for a company report — about as upbeat as in Q2 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Full figures

PLN · PAP Biznes report (2026-08-14)

Metric Q2 2026 Q2 2025 Change
Revenue 0 0
Operating income 2.6M 3.0M −11.0%
Net income 1.4M 1.4M −4.3%
P/E today 9.8 9.9 11.8 −1.9

Latest announcements

Official filings, newest first.

Similar companies

Healthcare · Drug Manufacturers—Specialty & Generic
All Healthcare companies →